Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Reassures ALS Patients In Final Development Guidance

Executive Summary

ALS advocates succeed in getting the FDA to soften its stance on use of randomized, placebo-controlled trials for drug development; final guidance also encourages patient-reported outcomes.

You may also be interested in...



BrainStorm’s Phase III Data Do Not Support Clinical Benefit Of NurOwn In ALS, US FDA Says

Agency’s unusual public statement about an investigational product's development status may be aimed at countering bullish comments from the sponsor; FDA cites failure of pivotal trial on the primary and secondary endpoints and ‘modest excess in deaths’ with the cell therapy.

Amylyx Drug Slows ALS Progression, Filings Imminent

Amylyx has raised just $75m to date, but that was enough to develop AMX0035 through a Phase II/III trial in which the drug slowed the progression of amyotrophic lateral sclerosis versus placebo.

Biogen Growth Continues, But Analysts Worry About Near-Term R&D Prospects

The biotech’s MS franchise led by Tecfidera grew strongly, while SMA therapy Spinraza dipped slightly, but Biogen maintains optimistic outlook amidst growing competition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS140884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel